GlassScriptPhysician profile
Orville V Murray
NPI 1700344686
$13,319.01
in general payments reported to CMS, 2019-2025
28 companies · $1,083 in 2025
The $1,083 reported for 2025 was more than what 82% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,067 · 2022: $6,624 · 2023: $1,290 · 2024: $1,255 · 2025: $1,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,614 · Education: $14.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,613.52 |
| Education | $14.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,246.35 | 2021-2025 | |
| Alkermes, INC. | $2,001.71 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Janssen Pharmaceuticals, INC | $877.33 | 2021-2025 | Spravato, Invega Sustenna |
| Corium, LLC | $785.90 | 2021-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $608.37 | 2021-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $519.90 | 2021-2024 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $444.77 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $389.07 | 2021-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $363.49 | 2021-2025 | Trintellix |
| Lundbeck LLC | $310.71 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $271.76 | 2021-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $263.48 | 2021-2022 | |
| Axsome Therapeutics, INC. | $259.84 | 2023-2025 | Auvelity, Sunosi |
| Ironshore Pharmaceuticals INC. | $181.18 | 2022-2024 | Jornay Pm |
| Validus Pharmaceuticals LLC | $150.74 | 2023-2025 | Equetro, Raldesy, Equetro |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $93.98 | 2023-2024 | Austedo Xr, Austedo |
| Eisai INC. | $93.35 | 2021-2022 | |
| Neos Therapeutics, LP | $78.91 | 2022-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Noven Therapeutics, LLC | $64.67 | 2022-2024 | Xelstrym |
| Bausch Health US, LLC | $61.90 | 2023-2025 | Aplenzin, Wellbutrin |
| Tris Pharma INC | $53.59 | 2022 | |
| Indivior INC. | $44.71 | 2022 | |
| Almatica Pharma LLC | $38.25 | 2024-2025 | Loreev Xr |
| Harmony Biosciences LLC | $35.62 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $25.60 | 2024 | |
| Adlon Therapeutics L.P. | $19.47 | 2021 | |
| Acadia Pharmaceuticals INC | $18.98 | 2025 | Nuplazid |
| Alfasigma USA, INC. | $15.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Orville Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.